CN103404934B - Hang-over solid beverage containing glutamine and preparation method thereof - Google Patents
Hang-over solid beverage containing glutamine and preparation method thereof Download PDFInfo
- Publication number
- CN103404934B CN103404934B CN201310374370.7A CN201310374370A CN103404934B CN 103404934 B CN103404934 B CN 103404934B CN 201310374370 A CN201310374370 A CN 201310374370A CN 103404934 B CN103404934 B CN 103404934B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- glutamine
- solid beverage
- lecithin
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 80
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 239000007787 solid Substances 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 206010019133 Hangover Diseases 0.000 title abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 54
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 39
- 239000000787 lecithin Substances 0.000 claims abstract description 39
- 235000010445 lecithin Nutrition 0.000 claims abstract description 39
- 229940067606 lecithin Drugs 0.000 claims abstract description 39
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 24
- 235000004279 alanine Nutrition 0.000 claims abstract description 24
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 23
- 229930182817 methionine Natural products 0.000 claims abstract description 23
- 210000004185 liver Anatomy 0.000 claims abstract description 22
- 241000219109 Citrullus Species 0.000 claims abstract description 19
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims abstract description 19
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims abstract description 19
- 239000000845 maltitol Substances 0.000 claims abstract description 19
- 229940035436 maltitol Drugs 0.000 claims abstract description 19
- 235000010449 maltitol Nutrition 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 21
- 239000008213 purified water Substances 0.000 claims description 21
- 238000005469 granulation Methods 0.000 claims description 14
- 230000003179 granulation Effects 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 7
- 239000008188 pellet Substances 0.000 claims description 7
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 6
- 201000005917 gastric ulcer Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 238000003672 processing method Methods 0.000 claims description 4
- 235000020985 whole grains Nutrition 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 28
- 210000002784 stomach Anatomy 0.000 abstract description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 6
- 150000004676 glycans Chemical class 0.000 abstract description 5
- 229920001282 polysaccharide Polymers 0.000 abstract description 5
- 239000005017 polysaccharide Substances 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 3
- 229930003268 Vitamin C Natural products 0.000 abstract description 3
- 235000019640 taste Nutrition 0.000 abstract description 3
- 235000019154 vitamin C Nutrition 0.000 abstract description 3
- 239000011718 vitamin C Substances 0.000 abstract description 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- 241000222355 Trametes versicolor Species 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 235000009508 confectionery Nutrition 0.000 abstract 1
- 230000027939 micturition Effects 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 97
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 239000000047 product Substances 0.000 description 31
- 230000035622 drinking Effects 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 13
- 235000013305 food Nutrition 0.000 description 12
- 238000001035 drying Methods 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 230000003908 liver function Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000010998 test method Methods 0.000 description 7
- 229910052785 arsenic Inorganic materials 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 4
- 206010070863 Toxicity to various agents Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 201000007930 alcohol dependence Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
- 229910052753 mercury Inorganic materials 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- 208000011906 peptic ulcer disease Diseases 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000011229 interlayer Substances 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000004916 vomit Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 230000002075 anti-alcohol Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- -1 arsenic salt Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 2
- 238000005220 pharmaceutical analysis Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000010117 shenhua Substances 0.000 description 2
- 125000003011 styrenyl group Chemical class [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000215 hyperchromic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a hang-over solid beverage containing glutamine and a preparation method thereof. The hangover solid beverage is mainly prepared from the following components in parts by weight: 20-30 parts of glutamine, 15-25 parts of alanine, 5-10 parts of methionine, 10-20 parts of ganoderan, 10-20 parts of coriolus versicolor polysaccharide, 10-15 parts of watermelon powder, 0.1-0.8 part of lecithin, 2-5 parts of VC (vitamin C), 2-5 parts of maltitol, 0.05-0.15 part of citric acid, and 1-3 parts of beta-cyclodextrin. The solid beverage has the effects of removing hang-over, protecting stomach and liver, promoting urination and improving immunity, tastes sour and sweet, safe to eat, concise, convenient to carry and long in preservation period and has a wide application range.
Description
Technical field
The invention belongs to field of food health care, be specifically related to a kind of Dealcoholic solid beverage containing glutamine and preparation method thereof.
Background technology
Characters of Chinese Alcoholic Drink Culture is of long standing and well established, and present wine has become a kind of medium.Show according to investigations, current China men and women drinks ratio respectively up to 84.1% and 29.3%, and in the crowd that drinks, 65% is unhealthy drinking, and its topmost problem is drunk beyond one's capacity.After excessive consumption of alcohol, can cause being still drank after a night, after drinking can the ill symptomses such as there are headache, dizziness a few days, feel run-down continuously, spirit is not propped up, serious also causing is poisoning, even dead.
Separate alcohol product and can reduce the concentration of ethanol and metabolite thereof in blood, alleviate its damage to each organ.Its effect is mainly manifested in three aspects: one, suppresses alcohol at gastrointestinal absorption, reduces ethanol and metabolite acetaldehyde concentration in blood thereof, reduce peak value; Its two, by increasing the capacity of decomposition of alcohol dehydrogenase and acetaldehyde dehydrogenase, the decomposition of accelerating alcohol and acetaldehyde; Its three, protection liver, strengthens the detoxification ability of liver.
Existing disintoxicating product on market, be mainly divided into antialcoholic drug to conciliate food and drink product, antialcoholic drug has side effect, more will focus on solution malaise symptoms after drinking; The food that relieves the effect of alcohol also only is improved and booster action, and effect is undesirable.In addition, the disintoxicating product on market, multi-functional greatly relatively single, be mainly applicable to the crowd of drinking, be suitable for crowd narrow.
Summary of the invention
The present situation large for market existing disintoxicating product side effect, DeGrain, function are relatively single, the crowd that is suitable for is narrow, the present invention aims to provide a kind of Dealcoholic solid beverage containing glutamine and preparation method thereof.
To achieve these goals, the present invention is by the following technical solutions:
Containing a Dealcoholic solid beverage for glutamine, the component primarily of following weight portion is made:
Glutamine 20 ~ 30 weight portion, alanine 15 ~ 25 weight portion, methionine 5 ~ 10 weight portion, GL-B 10 ~ 20 weight portion, coriolan 10 ~ 20 weight portion, watermelon powder 10 ~ 15 weight portion, lecithin 0.1 ~ 0.8 weight portion, VC(vitamin C) 2 ~ 5 weight portions, maltitol 2 ~ 5 weight portion, citric acid 0.05 ~ 0.15 weight portion, beta-schardinger dextrin-1 ~ 3 weight portion.
Preferably this solid beverage is made primarily of the component of following weight portion:
Glutamine 22 ~ 25 weight portion, alanine 18 ~ 22 weight portion, methionine 5 ~ 8 weight portion, GL-B 14 ~ 16 weight portion, coriolan 14 ~ 16 weight portion, watermelon powder 10 ~ 13 weight portion, lecithin 0.3 ~ 0.5 weight portion, VC3 ~ 4 weight portion, maltitol 2 ~ 4 weight portion, citric acid 0.08 ~ 0.12 weight portion, beta-schardinger dextrin-1.5 ~ 2.5 weight portion.
Most preferably this solid beverage is made primarily of the component of following weight portion:
Glutamine 25 weight portion, alanine 20 weight portion, methionine 6 weight portion, GL-B 15 weight portion, coriolan 15 weight portion, watermelon powder 10 weight portion, lecithin 0.4 weight portion, VC3.5 weight portion, maltitol 3 weight portion, citric acid 0.1 weight portion, beta-schardinger dextrin-2 weight portion.
Above-mentioned glutamine purity more than 98.5%, specific rotation+34.2 ~+36.20, pH4.9 ~ 5.7.Chloride≤0.020% in this glutamine, sulfate≤0.028%, heavy metal is less than 20/1000000ths, arsenic salt≤0.0002%, other amino acid≤0.4%.
The processing method of above-mentioned solid beverage comprises the steps:
A). lecithin is added in purified water, then adds beta-schardinger dextrin-, stir and obtain lecithin beta-schardinger dextrin-solution;
B). take glutamine in proportion, alanine, methionine, GL-B, coriolan, watermelon powder, VC, maltitol, citric acid, after mixing, add purified water, mixing granulation;
C) the lecithin beta-schardinger dextrin-solution that " a) " step prepares is added in the particle prepared to " b) " step, mixing granulation, whole grain; Be dried to dry pellet moisture≤5.0% temperature 60 ~ 65 DEG C, be cooled to room temperature, sieve.
The processing method of above-mentioned solid beverage preferably includes following steps:
A). lecithin is added in the purified water of lecithin 10 ~ 12 times of weight, then add beta-schardinger dextrin-, stir and obtain lecithin beta-schardinger dextrin-solution;
B). take glutamine in proportion, alanine, methionine, GL-B, coriolan, watermelon powder, VC, maltitol, citric acid, after mixing, add the purified water of this nine kinds of materials 0.1 ~ 0.3 times of weight, mixing granulation;
C) the lecithin beta-schardinger dextrin-solution that " a) " step prepares is added in the particle prepared to " b) " step, mixing granulation, the whole grain of 60 order; Be dried to dry pellet moisture≤5.0% temperature 60 ~ 65 DEG C, be cooled to room temperature, sieve.
Solid beverage of the present invention has excellent effect for liver of sobering up, protect, treatment gastric ulcer, develop immunitypty aspect.Glutamine of the present invention can be glutamine crude product after glutamine 10 ~ 15 times of purified water are dissolved, adopt ion-exchange chromatography, ion exchange column resin used is D306 macroreticular weakly base styrene series anion exchange resin, glutamine 20 ~ 30 times of purified water wash-outs are adopted to obtain glutamine chromatographic eluate, glutamine chromatographic eluate is temperature 60 ~ 65 DEG C, vacuum-1.0-(-0.09) be concentrated into the weight 5 ~ 6 times that concentrate is glutamine crude product under MPa condition, after glutamine concentrate is cooled to 50 ~ 55 DEG C, adding glutamine 1.5 times of weight concentrations is the ethanolic solution of 95%, leave standstill 6 ~ 10 hours, centrifugal coarse crystallization glutamine, dissolve through heavy 80 ~ 90 DEG C of purified water of coarse crystallization glutamine 5 ~ 6 times again, after adopting 0.2 ~ 1% lysate volume activity carbon decoloring, 80 ~ 90 DEG C are incubated 5 ~ 10 minutes, be cooled to 40 ~ 45 DEG C, adding lysate 0.8 times amount concentration is 95% ethanolic solution crystallization, the centrifugal glutamine that must be recrystallized.Recrystallization glutamine, temperature 70 ~ 80 DEG C, under vacuum-1.2 ~ (-1.0) MPa condition after vacuum drying, was pulverized 80 mesh sieves, was obtained glutamine.
The raw material adopted in the present invention's formula, glutamine content measures according to annex USP34-NF29, content >=98.6%; Alanine content detection method is according to document: content (Pharmaceutical Analysis magazine 2008, the 28(12) 1997-2000 of 4 kinds of primary amino acid in pre-column derivatization HPLC Simultaneously test donkey-hide gelatin) detect, content >=99%; The assay method that the assay of polysaccharide adopts the assay method (P15 ~ 19) of function composition " in the health food " (China Light Industry Press, 2002, Wang Guangya), ganoderma polyoses content >=30%, coriolan content >=35%.
Compared with existing disintoxicating product, the present invention has following outstanding advantage:
(1) formula of the present invention has and sobers up, nourishing the stomach, protects liver, improves immunity, regulates blood sugar, controls the effect such as blood pressure, heat-clearing, removing toxic substances.Glutamine and alanine associating, significantly can strengthen the detoxication to ethanol, aldehydes, obviously reduce ethanol, aldehydes to the injury of digestive system, nervous system, cardiovascular system, reproductive system etc., improve the protected effect to each system.Add methionine in formula and can promote liver plasma membrane phospholipid methylation; membrane fluidity is made to strengthen Na+, K+-ATP enzyme pumping action strong; can reduce after people drinks; the alluvial of bile in liver cell, turns sulfenyl effect and strengthens, thus enhance the synthesis of cysteine in liver cell, glutathione and taurine; decrease bile acid to build up in liver; strengthen detoxication, be conducive to liver cell and recover normal physiological function, impel jaundice to disappear and liver function recovery.Adding a certain amount of GL-B and coriolan respectively in formula, obviously can strengthen liver protection effect, improve immunity, cover GL-B bitter taste, is solid beverage flavouring of the present invention, hyperchromic.Add a certain amount of watermelon powder in formula, make formula have diuresis effect, the excretion of acceleration of alcohol, simultaneously for the present invention increases watermelon delicate fragrance; Add a certain amount of lecithin in formula and not only there is reduction cholesterol levels, protection liver, Improving memory power, develop immunitypty and lipotropic vigor, all right hydrotropy simultaneously, if addition is too much, Dealcoholic solid beverage of the present invention is oxidizable, there is rancidity, if addition is very few, then Dealcoholic solid beverage solute effect of the present invention is undesirable; In addition, inventor finds in R&D process: glutamine, alanine, after the mixing of methionine, GL-B and coriolan, instant capacity is undesirable, and after placing a period of time, the easy moisture absorption, oxidation, and then affect the shelf-life of product and eat, for this reason, inventor makes further research formula, VC and beta-schardinger dextrin-coupling can significantly improve the stability of product, and can shelter the micro-bitter taste in product; The ratio that the present invention's formula is also 2 ~ 5:0.05 ~ 0.15 according to weight ratio with the addition of maltitol and citric acid, and make taste of the present invention sour-sweet, local flavor is soft.
(2) formula effective ingredient used can directly be absorbed by the body, do not need to experience unnecessary conversion process, energy rapid catabolism enters the alcohol in body, reduces alcohol storage in vivo and stays the time, thus alleviate the damage of alcohol to each internal organs of human body to greatest extent, to human body safety.
(3) the present invention is easy to carry, edible succinct, can take after mixing it with water, also can directly pour in mouth, before wine, in wine, equal edible after drinking, takes effect best, take second place in wine before wine.
(4) to be suitable for crowd wide in the present invention; although its effect has obvious effect for alleviating the damage of alcohol to human body; even if but do not drink and wish to protect stomach and liver, health care people also edible; and have significant effect, solve the problem of disintoxicating product function singleness.
The present invention, by following experimental example, sets forth the main beneficial effect that the present invention has:
Experimental example 1 alcohol user takes the impact of Dealcoholic solid beverage of the present invention on human blood alcohol concentration
1 by the selection of test product and testing crew
1.1. by test product: Dealcoholic solid beverage 6g/ bag of the present invention (embodiment 1).
1.2 testing crews: the male sex at 30 ~ 55 years old age, body weight 65Kg(± 5%), the heart, Liver and kidney function are normal, do not have 20 abnormal male sex through health check-up.Testing crew exclusion standard:
(1) the liver function person that exceedes clinical normal range; (2) allergy, intestines and stomach, kidney, liver, HDH person is had; (3) alcoholism or drug poisoning medical history person is had; (4) start to test first 2 weeks oral administration medicament thing persons; (5) other persons of being not suitable for.
2 test methods
2.1 first 5 days of tests, the alcoholic food of fasting; The food of fasting identical type in first 10 hours that test the same day and experimental period.
2.2 adopt randomized double-blind experiment, experimenter are divided into test group and control group at random, 10/group.Before drinking 15 minutes, test group was taken by test product 6g, and control group takes comfort product 6g.
Allow experimenter in 30 minutes, drink 52 ° of five-Grain Liquor 200mL during 2.3 test.
2.4 experimenters after drinking in 5 hours, except drinking 52 ° of five-Grain Liquors, other any beverages of No drinking and edible any food.
2.5 experimenters take a blood sample once before drinking, drink latter 20 minutes, 40 minutes, 60 minutes, 2h, 4h, 6h, 8h, 10h, 16h respectively take a blood sample once.
2.6 pairs of institute's blood sampling Immediate managements, after removing protein, measure alcohol concentration with efficient liquid phase chromatographic analysis instrument.
2.7 tests are tested after 20 days alternately.
The change (see figure 1) of 2.8 experimenter's BACs.
Test group blood of human body concentration is starkly lower than control group, shows that Dealcoholic solid beverage of the present invention obviously can promote alcohol metabolism, significantly reduces BAC.
Test example 2 takes Dealcoholic solid beverage of the present invention to the drunk carry of people and the impact of time of sobering up before drinking
1 by the selection of test product and testing crew
1.1 by test product: Dealcoholic solid beverage 6g/ bag of the present invention (embodiment 1)
1.2 testing crews: the male sex that 20 30 ~ 55 years old ages often drink, body weight 65Kg(± 5%), the heart, Liver and kidney function are normal, not abnormal through health check-up.Testing crew exclusion standard:
(1) the liver function person that exceedes clinical normal range; (2) allergy, intestines and stomach, kidney, liver, HDH person is had; (3) alcoholism or drug poisoning medical history person is had; (4) start to test first 2 weeks oral administration medicament thing persons; (5) other persons of being not suitable for.
2 test methods
2.1 first 5 days of tests, the alcoholic food of fasting; The food of fasting identical type in first 10 hours that test the same day and experimental period.
2.2 adopt random double blind test, 20 experimenters are divided into test group and control group at random, 10 people/group.Drink first 15 minutes, test group is taken by test product 6g, and control group takes comfort product 6g.
2.3 drink speed: allow experimenter in 30 minutes, drink 52 ° of five-Grain Liquor 200mL during test, after drunk, forbid drinking, and record drunk personnel's drinking amount.
Drunk criterion:
(1) loquacity after drinking; (2) sleep; (3) speak with a lisp; (4) blush, vomit; (5) hello of speaking prolixity, incoherent.
2.4 in drunk latter 6 hours, except giving water 200mL/h, forbid other any beverages.
Experimenter is arranged in same peace and quiet, a home from home by 2.5, observes situation, record impression.
To sober up criterion: all drunk senses of discomfort and carry are eliminated completely, and health returns to the state before drinking completely.
2.6 tests, after 20 days, are tested alternately.
2.7 result of the tests are in table 1,2,3.
Table 1 Dealcoholic solid beverage of the present invention is on the impact (n=20) of the drunk amount of people
Table 2 Dealcoholic solid beverage of the present invention is on the impact (n=20) of the drunk rear carry of people
Table 3 solid beverage of the present invention is on the impact (n=20) of the time of sobering up
Test example 3, takes Dealcoholic solid beverage of the present invention to the drunk carry of people and the impact of time of sobering up in drinking
1 by the selection of test product and testing crew
1.1 by test product: Dealcoholic solid beverage 6g/ bag of the present invention (embodiment 1)
1.2 testing crews: the male sex that 20 30 ~ 55 years old ages often drink, body weight 65Kg(± 5%), the heart, Liver and kidney function are normal, not abnormal through health check-up.Testing crew exclusion standard:
(1) the liver function person that exceedes clinical normal range; (2) allergy, intestines and stomach, kidney, liver, HDH person is had; (3) alcoholism or drug poisoning medical history person is had; (4) start to test first 2 weeks oral administration medicament thing persons; (5) other persons of being not suitable for.
2 test methods
2.1 first 5 days of tests, the alcoholic food of fasting; The food of fasting identical type in first 10 hours that test the same day and experimental period.
2.2 adopt random double blind test, 20 experimenters are divided into test group and control group at random, 10 people/group.Start to drink latter 10 minutes, test group is taken by test product 6g, and control group takes comfort product 6g.
2.3 drink speed: allow experimenter in 30 minutes, drink 52 ° of five-Grain Liquor 200mL during test, after drunk, forbid drinking, and record drunk personnel's drinking amount.
Drunk criterion: (1) drink after loquacity; (2) sleep; (3) speak with a lisp; (4) blush, vomit; (5) hello of speaking prolixity, incoherent.
2.4 in drunk latter 6 hours, except giving water 200mL/h, forbid other any beverages.
Experimenter is arranged in same peace and quiet, a home from home by 2.5, observes situation, record impression.
To sober up criterion: all drunk senses of discomfort and carry are eliminated completely, and health returns to the state before drinking completely.
2.6 tests, after 20 days, are tested alternately.
2.7 result of the tests are in table 4,5,6.
Table 4 Dealcoholic solid beverage of the present invention is on the impact (n=20) of the drunk amount of people
Table 5 Dealcoholic solid beverage of the present invention is on the impact (n=20) of the drunk rear carry of people
Table 6 solid beverage of the present invention is on the impact (n=20) of the time of sobering up
Test example 4 takes Dealcoholic solid beverage of the present invention to the drunk carry of people and the impact of time of sobering up after drinking
1 by the selection of test product and testing crew
1.1 by test product: Dealcoholic solid beverage 6g/ bag of the present invention (embodiment 1)
1.2 testing crews: the male sex that 20 30 ~ 55 years old ages often drink, body weight 65Kg(± 5%), the heart, Liver and kidney function are normal, not abnormal through health check-up.Testing crew exclusion standard:
(1) the liver function person that exceedes clinical normal range; (2) allergy, intestines and stomach, kidney, liver, HDH person is had; (3) alcoholism or drug poisoning medical history person is had; (4) start to test first 2 weeks oral administration medicament thing persons; (5) other persons of being not suitable for.
2 test methods
2.1 first 5 days of tests, the alcoholic food of fasting; The food of fasting identical type in first 10 hours that test the same day and experimental period.
2.2 adopt random double blind test, 20 experimenters are divided into test group and control group at random, 10 people/group.After drinking in 5, test group and control group are taken respectively by test product and placebo 6g.
2.3 drink speed: allow experimenter in 30 minutes, drink 52 ° of five-Grain Liquor 200mL during test, after drunk, forbid drinking.
Drunk criterion: (1) drink after loquacity; (2) sleep; (3) speak with a lisp; (4) blush, vomit; (5) hello of speaking prolixity, incoherent.
2.4 in drunk latter 6 hours, except giving water 200mL/h, forbid other any beverages.
Experimenter is arranged in same peace and quiet, a home from home by 2.5, observes situation, record impression.
To sober up criterion: all drunk senses of discomfort and carry are eliminated completely, and health returns to the state before drinking completely.
2.6 tests, after 20 days, are tested alternately.
2.7 result of the tests are in table 7,8.
Table 7 Dealcoholic solid beverage of the present invention is on the impact (n=20) of the drunk rear carry of people
Table 8 solid beverage of the present invention is on the impact (n=20) of the time of sobering up
Experimental example 5 takes the impact of Dealcoholic solid beverage of the present invention on patients w ith peptic ulcer disease
1 by the selection of test product and testing crew
1.1 by test product: Dealcoholic solid beverage 6g/ bag of the present invention (embodiment 1).
1.2 testing crews: 60 male sex's patients w ith peptic ulcer diseases (Jinhu County First People's Hospital).
2 test methods
2.1 adopt randomized double-blind experiment, and 60 routine patients w ith peptic ulcer diseases are divided into test group and control group at random, 30 examples/group, the general clinical data of two groups of patients has comparativity.
2.2 test group edible for patients solid beverage of the present invention, 6g/ time, three times on the one; Control group eats placebo, 6g/ time, three times on the one.
2.3 observation of curative effect treatments the 3rd, 5,7 day, inquiry symptom improves situation, record bad reaction.
2.4 therapeutic evaluatioies are effective: symptom disappears completely; Effective: symptom is comparatively treated forward part and disappeared, seizure frequency reduces before comparatively treating or symptom more than half alleviates; Invalid: symptom is without improvement or increase the weight of.Efficient=(effective number of cases+effectively number of cases)/total number of cases × 100%.
Counting χ between 2.5 statistical analysis groups
2inspection, measurement data t checks, and P < 0.05 has conspicuousness for difference.
3 results
Test group the 3rd day total effective rate 80.3%(25/30), control group total effective rate 30.0% (9/30), two groups of differences have statistical significance; In the 7th day test group total effective rate 93.3%(28/30), control group total effective rate 33.3%(10/30), two groups of differences have statistical significance; 10th day, test group total effective rate 96.7%(29/30), control group total effective rate 36.7%(11/30) and, two groups of differences have statistical significance.In table 9.This result points out solid beverage of the present invention to have good efficacy to gastric ulcer.Two groups of patients are showed no obvious adverse reaction.
A table 9 liang group patients w ith peptic ulcer disease test effect compares
Note: P
3rd day< 0.05; P
7th day< 0.05; P
10th day< 0.05
Test example 6, Dealcoholic solid beverage liver protection effect of the present invention clinical testing
1 by the selection of test product and testing crew
1.1 by test product: Dealcoholic solid beverage 6g/ bag of the present invention (embodiment 1)
1.2 testing crews: Male Liver Cirrhosis Patients 60 example (Jinhu County First People's Hospital), 30 ~ 60 years old age.
Exclusion standard: (1) diabetic;
(2) tumor patient;
(3) severe cardiac, lung, nephrotic;
(4) other serious diseases.
2 test methods
2.1 adopt randomized double-blind experiment, and 60 routine chronic hepatitis patients are divided into test group and control group at random, 30 examples/group, the general clinical data of two groups of patients has comparativity.
2.2 test group edible for patients solid beverage of the present invention, 6g/ time, three times on the one; Control group eats placebo, 6g/ time, three times on the one.
2.3 observation of curative effect treatment before routine inspection liver function (comprising ALT, AST, TBIL, DBIL, TP, A/G etc.), before test, in monthly look into HBV-M, HBV, DNA.The medication phase asks and observes and record the change of clinical cardinal symptom and sign, and has no adverse reaction.
2.4 therapeutic evaluatioies are effective: symptom disappears completely; Effective: symptom is comparatively treated forward part and disappeared, seizure frequency reduces before comparatively treating or symptom more than half alleviates; Invalid: symptom is without improvement or increase the weight of.Efficient=(effective number of cases+effectively number of cases)/total number of cases × 100%.
6.2.5 statistical analysis: counting χ between group
2inspection, measurement data t checks, and P < 0.05 has conspicuousness for difference.
A table 11 liang group hepatitis test effect compares
Note: P < 0.05
Known by experimental result, solid beverage of the present invention can significantly improve gastric ulcer symptom, has the effect of protection stomach lining.
Test example 7 solid beverage of the present invention is on the impact of repeated infection patient immunity
1 by the selection of test product and testing crew
1.1 by test product: Dealcoholic solid beverage 6g/ bag of the present invention (embodiment 1)
The selection of 1.2 testing crews: hypoimmunity, repeatedly by male sex gerontal patient 60 people of bacterium, virus infections (Jinhu County the People's Hospital), condition is infect number of times in nearly 1 year to be greater than 5 times.Infect And Diagnose by pathogeny detection result, acute time indicator reaction (WBC, N% or CRP) and make a definite diagnosis in conjunction with clinical symptoms.Two groups of clinical datas compare, and through statistical test without significant (P>0.05), have comparativity.
Exclusion standard: (1) has serious endocrine and immune system disease patient;
(2) immunodepressant person is taken in the recent period;
(3) carry out operation in half a year and there is obvious open wound person.
2 test methods
Experimenter is divided into test group and control group by 2.1 at random, 30 people/group, control group: conventional anti-infection is treated, and does not use other immunomodulators; Treatment group: on conventional anti-infection treatment basis, add and use solid beverage of the present invention 6g/ time, three times on the 1st.
2.2 couples of two groups of patients distinguish before the treatment and treat 25 days collection limosis vein blood samples afterwards, adopt the full-automatic stream type cell analyzer of PARTEC CyFlow to measure CD3, CIM, CD8, CIM/CD8 level, adopt simultaneously and detect Immunoglobulin IgA, IgG, IgM level.
2.3 pairs of objects of observation are followed the tracks of after leaving hospital and are followed up a case by regular visits to 3 months, carry out statistical analysis to infection and recurrence situation, analyze and adopt χ between group
2analyze, data variance adopts t inspection.
3 result of the tests
Table 12 is tested T-lymphocyte Subsets measurement result and is compared
After treatment, test group compares with control group, P < 0.05.
Front and back determination of immunoglobulin results contrast tested by table 13
After treatment, test group compares with control group, P < 0.05.
After table 14 is treated, infection and recurrence situation compares
After treatment, test group compares with control group, P < 0.05.
Known by experimental result, solid beverage of the present invention significantly can improve hepatitis symptom, has liver-protective effect.
Solid beverage of the present invention has following features compared with the prior art: solid beverage of the present invention has sobers up, protects liver, treatment gastric ulcer, effect of develop immunitypty and raciness, and instant capacity is good, drinks conveniently, is easy to keep health.And, the sobering up of the present composition, protect the simple addition of liver, treatment gastric ulcer, develop immunitypty effect not each constituent function, but the exercising result of the Synergistic of each constituent.
Accompanying drawing explanation
Fig. 1 is that solid alcohol-decomposing beverage of the present invention is on the impact of human blood alcoholic strength
Detailed description of the invention
The present invention is further illustrated below by way of specific embodiment.But the detail of embodiment only for explaining the present invention, should not be construed as limited overall technical solution.
Solid beverage of the present invention, glutamine content measures according to annex USP34-NF29, alanine content is according to document: content (the Pharmaceutical Analysis magazine 2008 of 4 kinds of primary amino acid in pre-column derivatization HPLC Simultaneously test donkey-hide gelatin, 28(12) 1997-2000) detect, methionine measures according to Chinese Pharmacopoeia version annex VII A in 2010, GL-B, coriolan is according to the assay method (P15-19) of function composition " in the health food " (China Light Industry Press, 2002, Wang Guangya) detect, maltitol measures according to GB28307, microbiological indicator measures according to GB4789, moisture, plumbous, arsenic, mercury measures according to GB5009.
Glutamine content >=98.5%, specific rotation+34.2 ~+36.20, pH4.9 ~ 5.7, clear, colorless, chloride≤0.020%, sulfate≤0.028%, heavy metal is less than 20/1000000ths, arsenic salt≤0.0002%, other amino acid≤0.4%, loss on drying≤0.28%, residue on ignition≤0.1%, total number of bacteria≤800/g, yeast and mold number≤80/g, EHEC, live mite without.
Embodiment 1
(1) preparation of glutamine
The preparation of glutamine chromatographic eluate:
Glutamine crude product (food-grade, Xinjiang Fufeng Biotechnology Co., Ltd.), adds dissolving tank, adds 10 ~ 15 times of purified water and makes dissolving complete.Glutamine crude product solution is crossed D306 macroreticular weakly base styrene series anion exchange resin column chromatography, detect starting point with 0.2% ninhydrin-acetone soln, receive chromatographic solution.After chromatography terminates, then add glutamine 20 ~ 30 times of purified water wash-outs, receive eluent, with 0.2% ninhydrin-acetone soln endpoint detection, obtain chromatographic eluate, the dissolving water that elution fractions feeds intake as lower batch.
The preparation of glutamine concentrate:
Pump in concentration tank by above-mentioned glutamine chromatographic eluate, Vacuum Concentration has crystal to separate out to micro-, and concentrate volume is 5 ~ 6 times of glutamine crude product, thickening temperature 60 ~ 65 DEG C, vacuum-1.0-(-0.09) MPa.
Glutamine crystallization:
Above-mentioned glutamine concentrate is poured in crystallizing tank, opens interlayer cooling water, after solution to be concentrated temperature is down to 50 ~ 55 DEG C, add glutamine 1.5 times amount 95% ethanol while stirring, leave standstill 6 ~ 10 hours.Open to stir and crystallization be uniformly dispersed, centrifugation obtains coarse crystallization glutamine.Filtrate is reclaimed.
Recrystallization:
In dissolving Decolouring pot, add a certain amount of purified water, purified water is that glutamine wets 5 ~ 6 times of crystal, and interlayer is heated to 80 ~ 90 DEG C, adds coarse crystallization glutamine while stirring, makes to dissolve completely.Add 0.2 ~ 1% lysate volume activity carbon decoloring again, insulation, stirs 5 ~ 10 minutes, and filters while hot.Filtrate is poured into recrystallization pot, open interlayer cold water, after temperature is down to 40 ~ 45 DEG C, add 0.8 times amount 95% ethanol while stirring, leave standstill 8 ~ 12h.Open to stir and crystallization be uniformly dispersed, centrifugation, filtrate is reclaimed, a small amount of 95% ethanol washing of crystal.
Vacuum drying:
The wet crystal of recrystallization is transferred to low temperature drying case inner drying, bake out temperature 70 ~ 80 DEG C, vacuum-1.0-(-1.2) MPa.After drying, Universalpulverizer is pulverized, and crosses 80 mesh sieves.
Solid beverage proportioning: step (1) described glutamine 25 weight portion, alanine 20 weight portion, methionine 6 weight portion, GL-B (Jiangsu Shenhua Medicine Co., Ltd's production) 15 weight portions, coriolan (Jiangsu Shenhua Medicine Co., Ltd) 15 weight portion, watermelon powder 10 weight portion, lecithin 0.4 weight portion, VC3.5 weight portion, maltitol 3 weight portion, citric acid 0.1 weight portion, beta-schardinger dextrin-2 weight portion.
(2) preparation of solid beverage:
Lecithin is added in lecithin 10 times amount purified water, then add beta-schardinger dextrin-, with mixer stirring, lecithin and beta-schardinger dextrin-are scatter in water completely and obtain lecithin beta-schardinger dextrin-solution.
By glutamine, alanine, methionine, GL-B, coriolan, watermelon powder, VC, maltitol, citric acid, adds after mixing in wet granulator, adds the purified water of this nine kinds of materials 0.2 times of weight, mixing granulation 5 minutes; After adding the lecithin beta-schardinger dextrin-solution obtained again, mixing granulation 5 minutes.
After granulating, material adds in Fastgranulatemachine, and sieve number is 60 orders.
Wet granular is put into boiling drier, controls baking temperature 60 ~ 65 DEG C, be no more than 50 minutes drying time, dry pellet moisture≤5.0%.
After drying terminates, in boiling drier, pass into natural wind, cool 5 minutes, make temperature of charge be down to room temperature (less than 30 DEG C).
Dried particle removes meal through Highefficientpowersifter, and sieve number is 40 orders.
After testing: the primary quality measure of this embodiment solid alcohol-decomposing beverage is: glutamine 25.1g/100g, alanine 20.3g/100g, methionine 5.9g/100g, polysaccharide 10.3g/100g, moisture 3.2%.Microbiological indicator and lead, arsenic, mercury all meet GB7101-2003 solid beverage sanitary standard.
Embodiment 2
(1) preparation of glutamine is with embodiment 1
Solid beverage proportioning: glutamine 23 weight portion, alanine 22 weight portion, methionine 6 weight portion, GL-B 15 weight portion, coriolan 15 weight portion, watermelon powder 10 weight portion, lecithin 0.4 weight portion, VC3 weight portion, maltitol 3 weight portion, citric acid 0.1 weight portion, beta-schardinger dextrin-2.5 weight portion.
(2) preparation of solid beverage
Lecithin is added in 8 times amount purified water, add beta-schardinger dextrin-simultaneously, with mixer stirring, lecithin and beta-schardinger dextrin-are scatter in water completely and obtain lecithin beta-schardinger dextrin-solution.
By glutamine, alanine, methionine, GL-B, coriolan, watermelon powder, VC, maltitol, citric acid, adds in wet granulator, adds the purified water of this nine kinds of materials 0.1 times of weight, mixing granulation 5 minutes.Add after obtaining lecithin beta-schardinger dextrin-solution, mixing granulation 5 minutes.
After granulating, material adds in Fastgranulatemachine, and sieve number is 60 orders.
Wet granular is put into boiling drier, controls baking temperature 60 ~ 65 DEG C, be no more than 50 minutes drying time, dry pellet moisture≤5.0%.
After drying terminates, in boiling drier, pass into natural wind, cool 5 minutes, make temperature of charge be down to room temperature (less than 30 DEG C).
Dried particle removes meal through Highefficientpowersifter, and sieve number is 40 orders.
After testing: the primary quality measure of this embodiment solid alcohol-decomposing beverage is: glutamine 23.0/100g, alanine 20.0g/100g, methionine 5.8g/100g, polysaccharide 10.5g/100g, moisture 3.0%.Microbiological indicator and lead, arsenic, mercury all meet GB7101-2003 solid beverage sanitary standard.
Embodiment 3
(1) preparation of glutamine is with embodiment 1
Solid beverage proportioning: glutamine 30 weight portion, alanine 15 weight portion, methionine 8 weight portion, GL-B 12 weight portion, coriolan 12 weight portion, watermelon powder 14 weight portion, lecithin 0.4 weight portion, VC5 weight portion, maltitol 2.5 weight portion, citric acid 0.1 weight portion, beta-schardinger dextrin-1 weight portion.
(2) preparation of solid beverage
Lecithin is added in lecithin 12 times amount purified water, add beta-schardinger dextrin-simultaneously, with mixer stirring, lecithin and beta-schardinger dextrin-are scatter in water completely and obtain lecithin beta-schardinger dextrin-solution.
By glutamine, alanine, methionine, GL-B, coriolan, watermelon powder, VC, maltitol, citric acid, adds in wet granulator, adds the purified water of this nine kinds of materials 0.3 times of weight, mixing granulation 5 minutes.After adding lecithin beta-schardinger dextrin-solution, mixing granulation 5 minutes.
After granulating, material adds in Fastgranulatemachine, and sieve number is 60 orders.
Wet granular is put into boiling drier, controls baking temperature 60 ~ 65 DEG C, be no more than 50 minutes drying time, be dried to dry pellet moisture≤5.0%.
After drying terminates, in boiling drier, pass into natural wind, cool 5 minutes, make temperature of charge be down to room temperature (less than 30 DEG C).
Dried particle removes meal through Highefficientpowersifter, and sieve number is 40 orders.
After testing: the primary quality measure of this embodiment solid alcohol-decomposing beverage is: glutamine 29.7g/100g, alanine 20.2g/100g, methionine 6.0g/100g, polysaccharide 10.2g/100g, moisture 3.3%.Microbiological indicator and lead, arsenic, mercury all meet GB7101-2003 solid beverage sanitary standard.
Claims (9)
1., containing a Dealcoholic solid beverage for glutamine, it is characterized in that its component primarily of following weight portion is made:
Glutamine 20 ~ 30 weight portion, alanine 15 ~ 25 weight portion, methionine 5 ~ 10 weight portion, GL-B 10 ~ 20 weight portion, coriolan 10 ~ 20 weight portion, watermelon powder 10 ~ 15 weight portion, lecithin 0.1 ~ 0.8 weight portion, VC2 ~ 5 weight portion, maltitol 2 ~ 5 weight portion, citric acid 0.05 ~ 0.15 weight portion, beta-schardinger dextrin-1 ~ 3 weight portion; Described glutamine purity more than 98.5%, specific rotation+34.2 ~+36.2, pH4.9 ~ 5.7.
2. the Dealcoholic solid beverage containing glutamine according to claim 1, is characterized in that this solid beverage is made primarily of the component of following weight portion:
Glutamine 22 ~ 25 weight portion, alanine 18 ~ 22 weight portion, methionine 5 ~ 8 weight portion, GL-B 14 ~ 16 weight portion, coriolan 14 ~ 16 weight portion, watermelon powder 10 ~ 13 weight portion, lecithin 0.3 ~ 0.5 weight portion, VC3 ~ 4 weight portion, maltitol 2 ~ 4 weight portion, citric acid 0.08 ~ 0.12 weight portion, beta-schardinger dextrin-1.5 ~ 2.5 weight portion.
3. the Dealcoholic solid beverage containing glutamine according to claim 1, is characterized in that this solid beverage is made primarily of the component of following weight portion:
Glutamine 25 weight portion, alanine 20 weight portion, methionine 6 weight portion, GL-B 15 weight portion, coriolan 15 weight portion, watermelon powder 10 weight portion, lecithin 0.4 weight portion, VC3.5 weight portion, maltitol 3 weight portion, citric acid 0.1 weight portion, beta-schardinger dextrin-2 weight portion.
4. a processing method for the Dealcoholic solid beverage containing glutamine as described in claim 1,2 or 3, is characterized in that the method comprises the steps:
A). lecithin is added in purified water, then adds beta-schardinger dextrin-, stir and obtain lecithin beta-schardinger dextrin-solution;
B). take glutamine in proportion, alanine, methionine, GL-B, coriolan, watermelon powder, VC, maltitol, citric acid, after mixing, add purified water, mixing granulation;
C) the lecithin beta-schardinger dextrin-solution that " a) " step prepares is added in the particle prepared to " b) " step, mixing granulation, whole grain; Be dried to dry pellet moisture≤5.0% temperature 60 ~ 65 DEG C, be cooled to room temperature, sieve.
5. a processing method for the Dealcoholic solid beverage containing glutamine as described in claim 1,2 or 3, is characterized in that the method comprises the steps:
A). lecithin is added in the purified water of lecithin 10 ~ 12 times of weight, then add beta-schardinger dextrin-, stir and obtain lecithin beta-schardinger dextrin-solution;
B). take glutamine in proportion, alanine, methionine, GL-B, coriolan, watermelon powder, VC, maltitol, citric acid, after mixing, add the purified water of this nine kinds of materials 0.1 ~ 0.3 times of weight, mixing granulation;
C) the lecithin beta-schardinger dextrin-solution that " a) " step prepares is added in the particle prepared to " b) " step, mixing granulation, the whole grain of 40 ~ 60 order; Be dried to dry pellet moisture≤5.0% temperature 60 ~ 65 DEG C, be cooled to room temperature, sieve.
6. the Dealcoholic solid beverage containing glutamine as described in claim 1,2 or 3 is for the preparation of the purposes in the beverage of sobering up.
7. the Dealcoholic solid beverage containing glutamine as described in claim 1,2 or 3 is for the preparation of the purposes of protecting in the beverage of liver.
8. the purposes of Dealcoholic solid beverage in the beverage for the preparation for the treatment of gastric ulcer containing glutamine as described in claim 1,2 or 3.
9. the purposes of Dealcoholic solid beverage at the beverage for the preparation of develop immunitypty containing glutamine as described in claim 1,2 or 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310374370.7A CN103404934B (en) | 2013-08-24 | 2013-08-24 | Hang-over solid beverage containing glutamine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310374370.7A CN103404934B (en) | 2013-08-24 | 2013-08-24 | Hang-over solid beverage containing glutamine and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103404934A CN103404934A (en) | 2013-11-27 |
| CN103404934B true CN103404934B (en) | 2015-07-01 |
Family
ID=49598024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310374370.7A Active CN103404934B (en) | 2013-08-24 | 2013-08-24 | Hang-over solid beverage containing glutamine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103404934B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201800027A1 (en) | 2015-06-19 | 2018-06-29 | Харша Чигурупати | COMPOSITION OF SYNERGETIC DRINKS |
| CN106261362A (en) * | 2016-08-08 | 2017-01-04 | 南昌大学 | A kind of honeysuckle composition beverage with the liver protecting effect and preparation method |
| CN108295248A (en) * | 2018-04-10 | 2018-07-20 | 李钟� | A kind of health food with antialcoholism action |
| CN110292642A (en) * | 2019-07-17 | 2019-10-01 | 苏州德邻医疗科技有限公司 | It is not through the polyethylene glycol complex and preparation method thereof of blood-brain barrier |
| CN112868971A (en) * | 2021-02-26 | 2021-06-01 | 高涵 | Solid beverage with hangover alleviating and stomach protecting functions and preparation process thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100915772B1 (en) * | 2002-03-26 | 2009-09-04 | 후지 세유 가부시키가이샤 | Low-trans fats for confectionery and bakery fat compositions |
| KR100492628B1 (en) * | 2005-03-30 | 2005-06-03 | (주)엔돌핀에프앤비 | Funtional corn silk tea and method for preparing the same |
| DE102006018293A1 (en) * | 2006-04-20 | 2007-10-25 | Fresenius Kabi Deutschland Gmbh | Pediatric amino acid solution for parenteral nutrition |
| CN101190025A (en) * | 2006-12-01 | 2008-06-04 | 王颖 | Food for sobering-up, promoting digestion and protecting liver |
| CN101297704B (en) * | 2008-05-20 | 2012-07-04 | 溧阳市天目湖保健品有限公司 | Health care food for protecting liver and manufacturing method thereof |
| CN101766635B (en) * | 2008-12-31 | 2012-10-10 | 克科 | Composite for disintoxicating and sobering |
| CN101744846A (en) * | 2009-12-25 | 2010-06-23 | 福州汉方生物技术有限公司 | Edible mycotic composite amylase nutritional agent |
| CN102038867B (en) * | 2010-12-31 | 2013-04-24 | 北京迪诺基因科技有限公司 | Antialcoholismic composition and preparation method thereof |
-
2013
- 2013-08-24 CN CN201310374370.7A patent/CN103404934B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103404934A (en) | 2013-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103404934B (en) | Hang-over solid beverage containing glutamine and preparation method thereof | |
| CN108434231B (en) | Medicinal and edible Chinese medicinal composition for resisting drunkenness and dispelling effects of alcohol and preparation method thereof | |
| CN101095751B (en) | Medicinal composition having functions of removing chloasma and improving nutritional anemia and method for preparing the same | |
| CN105395919B (en) | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof | |
| CN104830588B (en) | It is a kind of it is anti-oxidant, relax bowel, the red wine of strengthen immunity and preparation method | |
| CN103585400B (en) | Have and strengthen immunologic function and the compositions alleviating fatigue effect and preparation method thereof | |
| CN109123612A (en) | A kind of composition with strengthen immunity, health food and preparation method thereof | |
| CN106214845A (en) | A kind of pharmaceutical composition with health care and preparation method thereof | |
| CN102894152B (en) | Health-care tea and preparation method thereof | |
| CN107163157B (en) | Schisandra chinensis acidic polysaccharose and its preparation method and application | |
| CN107468835A (en) | The composition of microbial fermentation cattail pollen and its application | |
| CN104352539B (en) | The extracting method of achyranthes aspera extract | |
| CN103830374B (en) | The application in hyperuricemia clearly of three leaf glycolipids | |
| CN109771457A (en) | Purposes of the russule extract in the preparation that preparation treatment and/or prevention high fat diet cause hepatic injury related disease | |
| EP3381459A1 (en) | Prophylactic and/or therapeutic agent for nafld/nash | |
| CN101143203B (en) | Compound oral liquid with liver-protecting and stomach-nourishing function | |
| CN107281317A (en) | A kind of oral liquid for improving body immunity and preparation method thereof | |
| CN107056959A (en) | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation | |
| CN111480846A (en) | Health-care product for assisting in reducing blood fat and improving immunity | |
| CN105360787A (en) | Health food and preparation method thereof | |
| CN1709335A (en) | Chinese medicine for treating infantile apositia and deficiency of vital energy of spleen and stomach, and its preparing method | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| CN106620351A (en) | Traditional Chinese medicine combination for treating and preventing flu and preparation method thereof | |
| CN110652574A (en) | Traditional Chinese medicine composition for preventing and treating non-alcoholic fatty liver disease and application thereof | |
| CN106420929A (en) | Application of fructus fici leaf extract and wintersweet flower extract in medicine or food for treating type II diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU FUFENG BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: JIANGSU SHENHUA PHARMACEUTICAL CO., LTD. Effective date: 20150505 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yue Zongcui Inventor after: Lin Jing Inventor after: Ma Menghua Inventor after: Zhao Fumei Inventor after: Xu Ling Inventor after: Qin Jianli Inventor after: Liu Xingzhong Inventor after: Dong Caihong Inventor before: Yue Zongcui Inventor before: Ma Menghua Inventor before: Zhao Fumei Inventor before: Xu Ling Inventor before: Qin Jianli |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: YUE ZONGCUI MA MENGHUA ZHAO FUMEI XU LING QIN JIANLI TO: YUE ZONGCUI LIN JING MA MENGHUA ZHAO FUMEI XU LING QIN JIANLI LIU XINGZHONG DONG CAIHONG |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150505 Address after: 211600 Jinhu, Jiangsu Province, Shenhua Road, No., No. 188 Applicant after: JIANGSU FUFENG BIOLOGICAL TECHNOLOGY CO., LTD. Address before: 211600 Jinhu, Jiangsu Province, Shenhua Road, No., No. 188 Applicant before: Jiangsu Shenhua Pharmaceutical Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220124 Address after: 211600 Shenhua Avenue 188, Jinhu County, Huaian City, Jiangsu Province Patentee after: JIANGSU SHENHUA PHARMACEUTICAL Co.,Ltd. Address before: 211600 Shenhua Avenue 188, Jinhu County, Huaian City, Jiangsu Province Patentee before: JIANGSU FUFENG BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right |